Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pacira Pharmaceuticals

25.54
-0.4350-1.68%
Volume:235.04K
Turnover:6.05M
Market Cap:1.18B
PE:-11.26
High:26.28
Open:26.25
Low:25.36
Close:25.97
Loading ...

Pacira Biosciences Up Over 17%, on Pace for Largest Percent Increase Since June 2020 -- Data Talk

Dow Jones
·
08 Apr

Pacira price target raised to $28 from $25 at Truist

TIPRANKS
·
08 Apr

Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives

TIPRANKS
·
08 Apr

Pacira BioSciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
08 Apr

RBC Raises Price Target on Pacira Biosciences to $26 From $22, Keeps Sector Perform Rating

MT Newswires Live
·
08 Apr

Pacira Biosciences Inc : H.c. Wainwright Raises Target Price to $65 From $48

THOMSON REUTERS
·
08 Apr

Pacira Biosciences Inc : RBC Raises Target Price to $26 From $22

THOMSON REUTERS
·
08 Apr

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Dow Jones
·
08 Apr

Pacira BioSciences Shares Rise 15% on Patent Settlement Over Exparel

Dow Jones
·
08 Apr

BUZZ-Pacira secures pain drug patent deal until 2030; shares up

Reuters
·
08 Apr

Pacira Biosciences Settles Patent Litigations Over Local Analgesic

MT Newswires Live
·
08 Apr

Pacira Pharmaceuticals Settles Patent Litigation with Fresenius

TIPRANKS
·
08 Apr

Pacira Biosciences Announces Settlement Of U.S. Patent Litigation For Exparel

Reuters
·
08 Apr

Pacira announces settlement of U.S. patent litigation for Exparel

TIPRANKS
·
08 Apr

Pacira Biosciences Announces Settlement of U.S. Patent Litigation for Exparel

THOMSON REUTERS
·
08 Apr

Pacira Biosciences Inc - Fresenius to Sell Generic Bupivacaine Without Limitations From 2039

THOMSON REUTERS
·
08 Apr

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

GlobeNewswire
·
08 Apr

RBC Capital Keeps Their Hold Rating on Pacira Pharmaceuticals (PCRX)

TIPRANKS
·
05 Apr

Pacira announces first patient dosed in Phase 2 ASCEND study of PCRX-201

TIPRANKS
·
03 Apr

BRIEF-Pacira Biosciences Announces First Patient Dosed In Phase 2 Study Evaluating Safety And Efficacy Of Pcrx-201 For The Treatment Of Osteoarthritis Of The Knee

Reuters
·
03 Apr